Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.

Capecchi, Pier Leopoldo; Lazzerini, Pietro Enea

Capecchi, Pier Leopoldo; Lazzerini, Pietro Enea.

Capecchi PL; Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
Lazzerini PE; Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

Ann Rheum Dis ; 81(11): e214, 2022 11.

Article in English | MEDLINE | ID: covidwho-2152922

Subject(s)

COVID-19 Drug Treatment; Antibodies, Monoclonal, Humanized/therapeutic use; Humans; Interleukin-6

Keywords

antirheumatic agents; cytokines; therapeutics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2020-218627

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google